FDA Determines Review Period for LAMZEDE Patent Boost
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for LAMZEDE, a special medicine, so its patent can be extended. This means the company behind LAMZEDE gets more time to protect their invention before others can copy it. If you’re in the business of making or selling medicines, this update affects when LAMZEDE’s patent rights expire and could impact market competition and profits.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
LAMZEDE Patent Extension Notice
If you make or sell medicines, the FDA has determined the regulatory review period for LAMZEDE so the company can seek a patent extension for this human biological product. That gives the company more time to protect its invention before others can copy it and may change when LAMZEDE’s patent rights expire, which could affect market competition and profits.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in